NCT06736587 Phase 1 Clinical Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DWP212525 in Healthy Volunteers
| NCT ID | NCT06736587 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Daewoong Pharmaceutical Co. LTD. |
| Condition | Autoimmune Diseases |
| Study Type | INTERVENTIONAL |
| Enrollment | 84 participants |
| Start Date | 2024-12-10 |
| Primary Completion | 2026-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 84 participants in total. It began in 2024-12-10 with a primary completion date of 2026-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The safety and tolerability of single and multiple administration of DWP212525
Eligibility Criteria
Inclusion Criteria: 1. Healthy adult volunteers aged 19 to 55 years 2. Those with a body weight ≥ 50.0 kg to ≤ 90.0 kg with a body mass index (BMI) of ≥ 18.0 kg/m2 to ≤ 30.0 kg/m2 3. Received a sufficient explanation on this study 4. Eligible as subjects in the study Exclusion Criteria: 1. History of diseases such as clinically significant disease of hepatobiliary 2. Following conditions applicable to clinically significant acute or chronic infections or the past history confirmed via an interview 3. Hemato-oncologic diseases, including malignant tumor diagnosis 4. Past history of tuberculosis infection or confirmed tuberculosis in the IGRA test and chest X-ray test
Frequently Asked Questions
Who can join the NCT06736587 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, up to 55 Years, studying Autoimmune Diseases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06736587 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06736587 currently recruiting?
Yes, NCT06736587 is actively recruiting participants. Visit ClinicalTrials.gov or contact Daewoong Pharmaceutical Co. LTD. to inquire about joining.
Where is the NCT06736587 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT06736587 clinical trial?
NCT06736587 is sponsored by Daewoong Pharmaceutical Co. LTD.. The trial plans to enroll 84 participants.